REGISTER
Allist’s 5‑Year Revenue Surge: Can the Pharma Dark Horse Keep Running?
Allist Pharmaceuticals’ H1 2026 revenue hit RMB 3.32 billion (+39.9% YoY), with net profit of RMB 1.54 billion (+46.6% YoY). Furmonertinib still accounts for 94.5% of sales, despite 8 rival third‑generation EGFR‑TKIs now on the market. The company is expanding into KRAS, RET, and ADC assets, while awaiting global Phase III readouts for furmonertinib and post‑NRDL uptake of its newer products.

On August 13, Allist Pharmaceuticals announced it had acquired Greater China rights to a MUC16/NaPi2b dual‑target ADC from its overseas partner ArriVent, with total upfront and milestone payments capped at USD 80.6 million. A week earlier, the company had disclosed its H1 2026 results: revenue of RMB 3.32 billion, up 39.85% year‑on‑year; net profit attributable to shareholders of RMB 1.54 billion, up 46.57%.

Behind these numbers, however, one drug still carries nearly all the weight. Furmonertinib, a third‑generation EGFR‑TKI, generated RMB 3.14 billion in first‑half sales, accounting for 94.5% of total revenue. Meanwhile, the number of approved third‑generation EGFR‑TKIs in China has now reached eight. How much differentiation does furmonertinib still have? What comes after resistance? Can a company built on a single blockbuster sell a multi‑target portfolio? This half‑year report and the ADC deal offer some clues.

I. Eight Rivals on the Same Field: How Much Differentiation Does Furmonertinib Have Left?

Furmonertinib was first approved in March 2021 for second‑line treatment of locally advanced or metastatic NSCLC with EGFR T790M mutation‑positive disease. It entered the National Reimbursement Drug List (NRDL) at the end of that year with a 79.35% price cut, generating RMB 236 million in sales in its first full year. In June 2022, the first‑line indication was approved and quickly included in the NRDL, after which sales entered a sustained growth phase, reaching RMB 5.12 billion in 2025.

At the time of its launch, the market already had a dominant player — AstraZeneca’s osimertinib — and a domestic competitor, Hansoh’s almonertinib, which had been approved earlier. Furmonertinib secured its position through clinical differentiation: better blood‑brain barrier penetration for brain metastases and lower incidence of diarrhea and rash. In February 2026, the second‑line indication for EGFR exon 20 insertion mutations (ex20ins) was approved, opening a new patient segment for the five‑year‑old product.

But the competitive landscape has changed dramatically. To date, eight third‑generation EGFR‑TKIs have been launched in China: osimertinib, almonertinib, furmonertinib, befotertinib, rizitinib, rezetinib, limertinib, and lazertinib. The market has entered a zero‑sum phase. Differentiation opportunities are narrowing: osimertinib has secured an early‑ to mid‑stage market entry through its lead in adjuvant therapy, while domestic alternatives such as almonertinib and befotertinib are closing the gap in NRDL coverage and indication expansion.

Furmonertinib’s own growth rate is also moderating. Revenue growth has declined from a peak of 235% to 46% in 2025, and sequential growth in the first half of 2026 was nearly flat. Its compound patent will expire in 2034. In the longer term, fourth‑generation EGFR‑TKIs could reshape the entire market; these agents target C797S mutations that arise after third‑generation drug resistance, and several companies in China have already advanced candidates to late‑stage clinical development.

II. Furmonertinib’s Unplayed Cards

The most notable pipeline development for furmonertinib is in EGFR PACC mutations. PACC mutations, along with T790M and ex20ins, are major EGFR mutation subtypes, accounting for approximately 12.5% of all EGFR mutations. Currently, no targeted therapy is approved for this population. In January 2026, the first‑line indication for furmonertinib in EGFR PACC‑mutant NSCLC was granted Breakthrough Therapy designation by China’s CDE.

Furmonertinib’s ongoing indication expansion is focused on three directions: first‑line treatment of rare mutations, adjuvant therapy in earlier‑stage disease, and brain metastases.

Global expansion is another track. Soon after furmonertinib’s initial approval in 2021, Allist out‑licensed overseas rights to ArriVent, a move widely regarded as one of China’s early “NewCo” models. Two global Phase III trials are now underway. Among them, the FURVENT study for first‑line ex20ins treatment has received FDA Breakthrough Therapy designation and is in the final follow‑up stage. If data are positive, furmonertinib could enter global markets around 2027, sidestepping the crowded domestic landscape — though this depends on the final readout from the global Phase III program.

III. What Comes After Resistance?

Resistance to third‑generation EGFR‑TKIs is the unavoidable next chapter for this class, and Allist’s strategy has three layers.

The first layer is fourth‑generation drug development. In March 2023, Allist in‑licensed ABK3376, a fourth‑generation EGFR inhibitor targeting C797S mutations, from Abbisko Therapeutics, aiming to address the clinical gap after third‑generation resistance — creating a pipeline that pairs a third‑generation workhorse with a fourth‑generation backup.

The second layer is combination therapy to extend furmonertinib’s lifecycle. The most mature data come from a combination with RC108, a c‑MET ADC from RemeGen. In a Phase Ib/II study of locally advanced or metastatic NSCLC with MET overexpression, patients with MET IHC ≥1+ and ≤20% tumor cells showing 3+ cytoplasmic staining had an objective response rate (ORR) of 40.5% and a median PFS of 7.1 months; those with MET IHC ≥3+ and ≤20% tumor cells showing 3+ cytoplasmic staining had an ORR of 61.1% and a median PFS of 8.2 months. The two companies are preparing a Phase III trial of the combination. These data are still from early‑stage studies, and whether they can translate into registrational evidence will depend on the Phase III results.

The third layer is the furmonertinib plus ABSK043 combination, developed jointly with Abbisko. ABSK043 is an oral small‑molecule PD‑L1 inhibitor. Phase II data showed good safety and tolerability, with no dose‑limiting toxicities or interstitial lung disease (ILD) observed; the most common treatment‑related adverse events were grade 1–2. Based on this safety profile, regulators have approved a study of the combination as first‑line therapy in treatment‑naïve EGFR‑mutant, PD‑L1‑positive NSCLC patients.

IV. From Single Product to Portfolio

The most significant new information in this half‑year report is that products beyond furmonertinib are beginning to contribute meaningful revenue.

Glecirasib is a highly selective, irreversible KRAS G12C inhibitor developed by Jacobio Pharmaceuticals. In 2024, Allist partnered with Jacobio to obtain Greater China rights. In May 2025, glecirasib was approved in China for KRAS G12C‑mutant advanced NSCLC patients who have received at least one prior systemic therapy, making it the third drug targeting this indication in the country. KRAS is the second most frequently mutated driver in lung cancer. After NRDL inclusion in early 2026, glecirasib ramped up quickly: RMB 62 million in Q1 and approximately RMB 68 million in Q2, totaling about RMB 130 million in the first half. Compared with furmonertinib’s RMB 3.14 billion in the same period, it is not yet a second pillar, but its growth trajectory is encouraging.

The RET inhibitor pralsetinib came from a commercial collaboration with CStone Pharmaceuticals in 2023, under which Allist obtained exclusive commercial promotion rights in mainland China. In the first half of 2026, it contributed approximately RMB 52 million in revenue. The patient population with RET fusion‑positive disease is relatively limited, so for now this product’s value lies more in filling out target coverage.

These two new products change more than just the revenue mix. In the past, Allist’s sales team could only promote furmonertinib. Now, with a portfolio covering EGFR, KRAS, and RET — three major lung cancer driver mutations — a single sales visit can offer physicians multiple treatment options, improving both department engagement and the efficiency of academic promotion. With a 1,800‑person commercial team now in place and selling expenses spread across multiple products, the company’s overall net profit margin rose to 46.57% in H1, while core net profit growth (50.99%) significantly outpaced revenue growth (39.85%).

The portfolio logic continues to extend outward. The MUC16/NaPi2b dual‑target ADC (AST12608/ARR‑002) acquired on August 13 marks Allist’s first step beyond lung cancer small‑molecule targeted therapy into the gynecologic oncology large‑molecule ADC space. The NaPi2b target has previously seen setbacks from companies including Mersana; this dual‑target ADC is designed to simultaneously target MUC16 and NaPi2b to overcome heterogeneity in single‑target expression and widen the therapeutic window. According to the partner, it is a potential first‑in‑class drug. Its IND was approved by the FDA in May 2026, with a Phase I trial planned for the second half of this year — no human data are yet available. The deal is capped at USD 80.6 million, with no small amount of risk, but for a company with a debt‑to‑asset ratio below 10% and no interest‑bearing debt, the cost is manageable — more akin to an early strategic bet made when cash is plentiful.

Returning to the opening question. Furmonertinib’s established base, slowing growth, and eight competitors on the same field are all already facts. How the second half plays out depends on three cards yet to be turned: the overseas data readout from the FURVENT study, which will determine whether furmonertinib can enter global markets around 2027; how quickly glecirasib scales up post‑NRDL, which will decide whether it can grow into a billion‑renminbi second pillar; and when AST12608 achieves first‑patient dosing, which will determine whether this foray into large‑molecule ADCs is a strategic move or a costly experiment. The growth in this half‑year report is already confirmed. The answers beyond the report will take a little longer.

0
0
Loading